Nucleic acid damage using riboflavin and light
CA 2495909 C · Owner: Caridianbct Biotechnologies, Llc · Inventors: Keil, Shawn D.; Goodrich, Raymond P.; Lockerbie, Robert Owen
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A process for damaging and maintaining damage to the nucleic acids of pathogens such as white blood cells, bacteria and viruses which may be contained in blood or blood components. This process comprises adding to the blood or blood component containing pathogens an effective amount of riboflavin, and exposing the fluid to light of an appropriate wavelength to damage the nucleic acid of the pathogen and to substantially maintain the damage to the pathogenic nucleic acids to allow for subsequent transfusion into a recipient.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 25, 2003 and granted February 21, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 25, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 25, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.